A Significant Step Forward in Dermatological Care A recent publication in JAMA Dermatology has brought exciting news for those navigating the complexities of dermatomyositis. The findings from the Phase 3 VALOR trial highlight the efficacy of brepocitinib, a novel therapeutic agent, in addressing the specific skin-related symptoms associated with this rare autoimmune condition. Understanding the…